{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T17:37:58Z","timestamp":1775065078405,"version":"3.50.1"},"reference-count":35,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2026,3,4]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess whether fluticasone furoate (FF) use, compared with budesonide (BUD), is associated with fewer clinically detected COVID-19 events among inhaled corticosteroids (ICS) users, and to explore virus-specificity using influenza as a comparator outcome. We hypothesised that FF may provide strong local anti-inflammatory effects with limited systemic immunosuppression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective cohort with outpatient follow-up over 4 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Single Japanese medical centre.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>334 adults (102 ICS users; 232 non-ICS) followed from July 2020 to July 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>Clinically detected COVID-19 (primary) and influenza (secondary). The primary exposure comparison was FF versus BUD among ICS users; ICS versus non-ICS was analysed secondarily (exploratory). Cox proportional hazards and logistic regression are adjusted for demographics, comorbidities, vaccination and systemic corticosteroids.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy-nine COVID-19 and 14 influenza events occurred. Among ICS users, FF was associated with fewer clinically detected COVID-19 events than BUD (adjusted HR 0.12, 95%\u2009CI 0.02 to 0.73; crude 6.5% vs 32.3%; Fisher\u2019s exact p=0.0047). Under symptom-based testing, ICS users also had fewer clinically detected COVID-19 events than non-ICS users (adjusted HR 0.46, 95%\u2009CI 0.22 to 0.94), although this comparison is limited by baseline imbalance and should be interpreted as exploratory and non-causal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Under symptom-triggered testing, FF was associated with fewer clinically detected COVID-19 events than BUD in the head-to-head comparison among ICS users. The ICS versus non-ICS comparison is exploratory due to confounding by indication and structural imbalance. These findings are hypothesis-generating and warrant prospective studies with systematic testing and stronger designs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjresp-2025-003800","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T15:35:26Z","timestamp":1775057726000},"page":"e003800","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Differential association of fluticasone furoate and budesonide with clinically detected COVID-19: a retrospective cohort study"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2143-8062","authenticated-orcid":false,"given":"Masaki","family":"Tsunemi","sequence":"first","affiliation":[{"name":"Tsurumi Medical Center, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8007-1516","authenticated-orcid":false,"given":"Kozo","family":"Kuribayashi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Ishimura","sequence":"additional","affiliation":[{"name":"Meijibashi Hospital, Matsubara, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5813-763X","authenticated-orcid":false,"given":"Kiyokazu","family":"Yoshinoya","sequence":"additional","affiliation":[{"name":"Sennansinge Clinic, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Tokyo Tower View Clinic Azabujuban, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Muto","sequence":"additional","affiliation":[{"name":"Shuutetsukai MUTO CLINIC, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Tsurumi Medical Center, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4249-4021","authenticated-orcid":false,"given":"Takashi","family":"Kijima","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"2026040108350670000_13.1.e003800.1","unstructured":"World Health Organization . Coronavirus disease (COVID-19) pandemic [Internet]. Geneva, 2024. Available: https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/coronavirus-disease-2019"},{"key":"2026040108350670000_13.1.e003800.2","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00812-20","article-title":"Pandemic COVID-19 joins History\u2019s Pandemic Legion","volume":"11","author":"Morens","year":"2020","journal-title":"mBio"},{"key":"2026040108350670000_13.1.e003800.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00869-2"},{"key":"2026040108350670000_13.1.e003800.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01585-9"},{"key":"2026040108350670000_13.1.e003800.5","unstructured":"World Health Organization . Ending the COVID-19 emergency and transitioning from emergency phase to longer-term disease management: guidance on calibrating the response. Geneva, 2023. Available: https:\/\/www.who.int\/publications\/i\/item\/WHO-WHE-SPP-2023.2"},{"key":"2026040108350670000_13.1.e003800.6","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12637"},{"key":"2026040108350670000_13.1.e003800.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.09.034"},{"key":"2026040108350670000_13.1.e003800.8","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.655666","article-title":"Fluticasone propionate suppresses Poly(I:C)-Induced ACE2 in Primary Human Nasal Epithelial Cells","volume":"11","author":"Nakazono","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"2026040108350670000_13.1.e003800.9","doi-asserted-by":"crossref","DOI":"10.1186\/1465-9921-8-54","article-title":"Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate","volume":"8","author":"Valotis","year":"2007","journal-title":"Respir Res"},{"key":"2026040108350670000_13.1.e003800.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.07.028"},{"key":"2026040108350670000_13.1.e003800.11","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S2213-2600(21)00160-0","article-title":"Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial","volume":"9","author":"Ramakrishnan","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026040108350670000_13.1.e003800.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01744-X"},{"key":"2026040108350670000_13.1.e003800.13","first-page":"1085","article-title":"Inhaled fluticasone furoate for outpatient treatment of COVID-19: the ACTIV-6 randomized clinical trial","volume":"330","author":"Boulware","year":"2023","journal-title":"JAMA"},{"key":"2026040108350670000_13.1.e003800.14","doi-asserted-by":"publisher","DOI":"10.1177\/0003489415606449"},{"key":"2026040108350670000_13.1.e003800.15","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00130-2021","article-title":"Inhaled corticosteroids downregulate SARS-CoV-2-related genes in COPD: results from a randomised controlled trial","volume":"58","author":"Milne","year":"2021","journal-title":"Eur Respir J"},{"key":"2026040108350670000_13.1.e003800.16","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02852-20","article-title":"Long-term modeling of SARS-CoV-2 Infection of In Vitro Cultured Polarized Human Airway Epithelium","volume":"11","author":"Hao","year":"2020","journal-title":"mBio"},{"key":"2026040108350670000_13.1.e003800.17","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0602-4"},{"key":"2026040108350670000_13.1.e003800.18","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-021-02983-5","article-title":"SARS-CoV-2 infection induces a pro-inflammatory cytokine response through cGAS-STING and NF-\u03baB","volume":"5","author":"Neufeldt","year":"2022","journal-title":"Commun Biol"},{"key":"2026040108350670000_13.1.e003800.19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009128","article-title":"SARS-CoV-2 spike protein promotes IL-6 trans-signaling by activation of angiotensin II receptor signaling in epithelial cells","volume":"16","author":"Patra","year":"2020","journal-title":"PLoS Pathog"},{"key":"2026040108350670000_13.1.e003800.20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1089\/jir.2022.0029","article-title":"Comparing the cytokine storms of COVID-19 and pandemic influenza","volume":"42","author":"Pacheco-Hern\u00e1ndez","year":"2022","journal-title":"J Interferon Cytokine Res"},{"key":"2026040108350670000_13.1.e003800.21","doi-asserted-by":"publisher","DOI":"10.7326\/M20-0504"},{"key":"2026040108350670000_13.1.e003800.22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008407","article-title":"Chemical intervention of influenza virus mRNA nuclear export","volume":"16","author":"Esparza","year":"2020","journal-title":"PLoS Pathog"},{"key":"2026040108350670000_13.1.e003800.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"2026040108350670000_13.1.e003800.24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.12839.e4"},{"key":"2026040108350670000_13.1.e003800.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2011.08.022"},{"key":"2026040108350670000_13.1.e003800.26","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706736"},{"key":"2026040108350670000_13.1.e003800.27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1164\/rccm.202003-0821OC","article-title":"COVID-19-related genes in sputum cells in asthma: relationship to demographic features and corticosteroids","volume":"202","author":"Peters","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2026040108350670000_13.1.e003800.28","doi-asserted-by":"publisher","DOI":"10.1126\/science.1214935"},{"key":"2026040108350670000_13.1.e003800.29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1009418","article-title":"Drug-induced resistance evolution necessitates less aggressive treatment","volume":"17","author":"Kuosmanen","year":"2021","journal-title":"PLoS Comput Biol"},{"key":"2026040108350670000_13.1.e003800.30","doi-asserted-by":"publisher","DOI":"10.7326\/M20-3012"},{"key":"2026040108350670000_13.1.e003800.31","doi-asserted-by":"crossref","first-page":"706902","DOI":"10.3389\/fgene.2021.706902","article-title":"Th2\/Th1 cytokine imbalance is associated with higher COVID-19 risk mortality","volume":"12","author":"Pavel","year":"2021","journal-title":"Front Genet"},{"key":"2026040108350670000_13.1.e003800.32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40249-023-01086-z","article-title":"Increased interleukin-6 is associated with long COVID-19: a systematic review and meta-analysis","volume":"12","author":"Yin","year":"2023","journal-title":"Infect Dis Poverty"},{"key":"2026040108350670000_13.1.e003800.33","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s15010-018-1229-y","article-title":"Inhaled corticosteroids and risk of upper respiratory tract infection in patients with asthma: a meta-analysis","volume":"47","author":"Yang","year":"2019","journal-title":"Infection"},{"key":"2026040108350670000_13.1.e003800.34","doi-asserted-by":"crossref","first-page":"D49","DOI":"10.1016\/j.vaccine.2008.07.039","article-title":"The biology of influenza viruses","volume":"26 Suppl 4","author":"Bouvier","year":"2008","journal-title":"Vaccine (Auckl)"},{"key":"2026040108350670000_13.1.e003800.35","unstructured":"Global Initiative for Asthma (GINA) . Global Strategy for Asthma Management and Prevention (2023 update), Available: https:\/\/ginasthma.org\/gina-reports [Accessed 29 Jul 2025]."}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2025-003800","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T15:35:29Z","timestamp":1775057729000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2025-003800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,4,1]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/bmjresp-2025-003800"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2025-003800","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}